National trends in the office-based treatment of children, adolescents, and adults with antipsychotics

Archives of General Psychiatry

Volumn 69, Issue 12, 2012, Pages 1247-1256

  Olfson, Mark ^a   Blanco, Carlos ^a   Liu, Shang Min ^a   Wang, Shuai ^a   Correll, Christoph U ^b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; DULOXETINE; LAMOTRIGINE; LITHIUM CARBONATE; LITHIUM CITRATE; NEUROLEPTIC AGENT; PROCHLORPERAZINE EDISYLATE; PROMETHAZINE; TRAZODONE; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; BIPOLAR DISORDER; CHILD; CONTROLLED STUDY; DEPRESSION; DISRUPTIVE BEHAVIOR; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEWBORN; OUTPATIENT; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; PSYCHIATRIST; SCHOOL CHILD; TREND STUDY;

EID: 84870603148     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2012.647     Document Type: Article

References (78)

1. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59(5):507-514.
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184.
3. Top therapeutic classes by US sales. IMS website. http://www.imshealth. com /deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top- line%20Market%20Data/2010%20Top-Therapeutic-Classes-by-Sales.pdf Updated April 7, 2011. Accessed October 30, 2011.
4. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269-284.
5. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009;23(10):837-855.
6. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs. 2010;24(7):575-593.
7. Malhi GS, Adams D, Cahill CM, Dodd S, Berk M. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs. 2009;69(15):2063-2101.
8. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109-127.
9. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655-670.
10. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006; 6(2):79-83. (Pubitemid 43960577)
11. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685. (Pubitemid 43848299)
12. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry. 2011;168 (10):1057-1065.
13. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotic drugs: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781.
14. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv. 2009;60(9):1175-1181.
15. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129.
16. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609- 616.
17. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144-158.
18. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-1369.
19. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107.
20. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008; 42(9):1316-1322.
21. Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, Chandra M, Reed G, Gurwitz JH. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135-1141.
22. Paus T, KeshavanM, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci. 2008;9(12):947-957.
23. Frick PJ, Lahey BB, Applegate B, Kerdyck L, Ollendick T, Hynd GW, Garfinkel B, Greenhill L, Biederman J, Barkley RA, McBurnett K, Newcorn J, Waldman I. DSM-IV field trials for the disruptive behavior disorders: symptom utility estimates. J Am Acad Child Adolesc Psychiatry. 1994;33(4):529-539. (Pubitemid 24133072)
24. Nguyen L, Huang LN, Arganza GF, Liao Q. The influence of race and ethnicity on psychiatric diagnoses and clinical characteristics of children and adolescents in children's services. Cultur Divers Ethnic Minor Psychol. 2007;13(1):18-25. (Pubitemid 46106968)
25. Yeh M, McCabe K, Hurlburt M, Hough R, Hazen A, Culver S, Garland A, Landsverk J. Referral sources, diagnoses, and service types of youth in public outpatient mental health care: a focus on ethnic minorities. J Behav Health Serv Res. 2002; 29(1):45-60. (Pubitemid 34150319)
26. Garland AF, Hough RL, McCabe KM, Yeh M, Wood PA, Aarons GA. Prevalence of psychiatric disorders in youths across five sectors of care. J Am Acad Child Adolesc Psychiatry. 2001;40(4):409-418. (Pubitemid 32242524)
27. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):9-14.
28. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64(9):1032-1039. (Pubitemid 47360848)
29. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck PC. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics. 2009;124(5):1395-1403.
30. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. J Clin Psychiatry. 2009;70(6):906-912.
31. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. (Pubitemid 37432885)
32. Sham PC, MacLean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand. 1994;89 (2):135-141. (Pubitemid 24047680)
33. 2009 NAMCS micro-data file documentation. National Center for Health Statistics/Centers for Disease Control and Prevention website. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Dataset-Documentation/NAMCS/doc09. pdf. Accessed February 12, 2012.
34. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12):1616-1627.
35. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: ameta-analysis. Lancet. 2009;373(9657):31-41.
36. Population estimates. United States Bureau of the Census website. http://www .census.gov/popest/. Accessed November 1, 2011.
37. Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report. 2008(3):1-39.
38. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010;121(1):4-10.
39. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31(3):465-471.
40. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):9-14.
41. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346. (Pubitemid 34832715)
42. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J AmAcad Child Adolesc Psychiatry. 2002; 41(9):1026-1036. (Pubitemid 38338050)
43. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders: results of a 2-year extension study. Eur Child Adolesc Psychiatry. 2006;15(2):97-104. (Pubitemid 43352183)
44. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116-141.
45. Blader JC. Acute inpatient care for psychiatric disorders in the United States, 1996 through 2007. Arch Gen Psychiatry. 2011;68(12):1276-1283.
46. Galanter CA, Pagar DL, Oberg PP, Wong C, Davies M, Jensen PS. Symptoms leading to a bipolar diagnosis: a phone survey of child and adolescent psychiatrists. J Child Adolesc Psychopharmacol. 2009;19(6):641-647.
47. Pogge DL, Wayland-Smith D, Zaccario M, Borgaro S, Stokes J, Harvey PD. Diagnosis of manic episodes in adolescent inpatients: structured diagnostic procedures compared to clinical chart diagnoses. Psychiatry Res. 2001;101(1): 47-54. (Pubitemid 32167114)
48. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3(4):333-337.
49. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. Arch Intern Med. 1999; 159(19):2263-2270. (Pubitemid 29501525)
50. Cates ME, Jackson CW, Feldman JM, Stimmel AE, Woolley TW. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45(4):251-254.
51. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry. 2008;20(1):15-20. (Pubitemid 351302398)
52. Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, Ford DE. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60(2):121-128. (Pubitemid 36173118)
53. Sohler NL, Walkup J, McAlpine D, Boyer C, Olfson M. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv. 2003;54(9):1258-1263. (Pubitemid 37055988)
54. Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv. 2006;57(1):133-136. (Pubitemid 43053850)
55. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery WB, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4): 482-488. (Pubitemid 46640638)
56. Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003; 29(2):183-193. (Pubitemid 37187683)
57. Depp C, Ojeda VD, Mastin W, Unützer J, Gilmer TP. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001-2004. Psychiatr Serv. 2008;59(10):1169-1174.
58. Patel NC, DelBello MP, Keck PE Jr, Strakowski SM. Ethnic differences in maintenance antipsychotic prescription among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15(6):938-946. (Pubitemid 43042985)
59. Cooper LA, Gonzales JJ, Gallo JJ, Rost KM, Meredith LS, Rubenstein LV, Wang NY, Ford DE. The acceptability of treatment for depression among African- American, Hispanic, and white primary care patients. Med Care. 2003;41(4): 479-489.
60. Mojtabai R. Americans' attitudes toward psychiatric medications: 1998-2006. Psychiatr Serv. 2009;60(8):1015-1023.
61. McLeod JD, Pescosolido BA, Takeuchi DT, White TF. Public attitudes toward the use of psychiatric medications for children. J Health Soc Behav. 2004;45(1):53-67. (Pubitemid 41449085)
62. Pescosolido BA, Perry BL, Martin JK, McLeod JD, Jensen PS. Stigmatizing attitudes and beliefs about treatment and psychiatric medications for children with mental illness. Psychiatr Serv. 2007;58(5):613-618. (Pubitemid 46841881)
63. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): part II. J Am Acad Child Adolesc Psychiatry. 2003;42(2):145-161. (Pubitemid 39610594)
64. Mandell DS, Thompson WW, Weintraub ES, Destefano F, Blank MB. Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnoses. Psychiatr Serv. 2005;56(1):56-62. (Pubitemid 40094471)
65. Coo H, Ouellette-Kuntz H, Lloyd JEV, Kasmara L, Holden JJ, Lewis ME. Trends in autism prevalence: diagnostic substitution revisited. J Autism Dev Disord. 2008; 38(6):1036-1046.
66. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647-656.
67. Frank RG, Garfield RL. Managed behavioral health care carve-outs: past performance and future prospects. Annu Rev Public Health. 2007;28:303-320. (Pubitemid 46833345)
68. Appelbaum PS. The 'quiet' crisis in mental health services. Health Aff (Millwood). 2003;22(5):110-116. (Pubitemid 41388726)
69. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry. 2008;65(8):962-970.
70. Mojtabai R. Americans' attitudes toward mental health treatment seeking: 1990-2003. Psychiatr Serv. 2007;58(5):642-651. (Pubitemid 46841886)
71. Sernyak M, Rosenheck R. Experience of VA psychiatrist with pharmaceutical detailing of antipsychotic medications. Psychiatr Serv. 2007;58(10):1292-1296. (Pubitemid 350043579)
72. Spielmans GI. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med. 2009;69(1):14-20.
73. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736-743. (Pubitemid 40942420)
74. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30(9):942-951.
75. Findling RL. Dosing of atypical antipsychotics in children and adolescents. Primary Care Companion J Clin Psychiatry. 2003;5(suppl 6):10-13. http://www.psychiatrist.com/pcc/pccpdf/v05s06/v05s0603.pdf. Accessed February 18, 2012.
76. Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McFarland BH. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry. 2008;69(10):1540-1547.
77. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
78. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2010. IMS website. http://www.imshealth.com/ deployedfiles/imshealth /Global/Content/IMS%20Institute/Static%20File/IHII- UseOfMed-report.pdf. Accessed February 10, 2012.